IL233351A - Use of apolipoprotein a – iv without glycosylation for the preparation of diabetes medications - Google Patents

Use of apolipoprotein a – iv without glycosylation for the preparation of diabetes medications

Info

Publication number
IL233351A
IL233351A IL233351A IL23335114A IL233351A IL 233351 A IL233351 A IL 233351A IL 233351 A IL233351 A IL 233351A IL 23335114 A IL23335114 A IL 23335114A IL 233351 A IL233351 A IL 233351A
Authority
IL
Israel
Prior art keywords
medicaments
diabetes
preparation
treatment
glycosylated apolipoprotein
Prior art date
Application number
IL233351A
Other languages
English (en)
Hebrew (he)
Other versions
IL233351A0 (en
Original Assignee
University Of Cincinnati
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2012/021802 external-priority patent/WO2012100010A1/en
Application filed by University Of Cincinnati filed Critical University Of Cincinnati
Publication of IL233351A0 publication Critical patent/IL233351A0/en
Publication of IL233351A publication Critical patent/IL233351A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL233351A 2012-01-19 2014-06-24 Use of apolipoprotein a – iv without glycosylation for the preparation of diabetes medications IL233351A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2012/021802 WO2012100010A1 (en) 2011-01-19 2012-01-19 Apolipoprotein aiv as an antidiabetic peptide
US201261675692P 2012-07-25 2012-07-25
PCT/US2012/066314 WO2013109342A1 (en) 2012-01-19 2012-11-21 Method of treating diabetes using non-glycosylated apolipoprotein a-iv

Publications (2)

Publication Number Publication Date
IL233351A0 IL233351A0 (en) 2014-08-31
IL233351A true IL233351A (en) 2016-12-29

Family

ID=48799573

Family Applications (1)

Application Number Title Priority Date Filing Date
IL233351A IL233351A (en) 2012-01-19 2014-06-24 Use of apolipoprotein a – iv without glycosylation for the preparation of diabetes medications

Country Status (13)

Country Link
US (1) US9951120B2 (enExample)
EP (1) EP2804618B1 (enExample)
JP (1) JP6310398B2 (enExample)
KR (1) KR20140117565A (enExample)
CN (1) CN104066436B (enExample)
AU (1) AU2012366182B2 (enExample)
BR (1) BR112014017141A2 (enExample)
CA (1) CA2860782A1 (enExample)
EA (1) EA028230B1 (enExample)
HK (1) HK1203823A1 (enExample)
IL (1) IL233351A (enExample)
MX (1) MX357071B (enExample)
WO (1) WO2013109342A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012207301B2 (en) 2011-01-19 2016-05-19 University Of Cincinnati Apolipoprotein AIV as an antidiabetic peptide
AU2012366182B2 (en) 2012-01-19 2017-08-17 University Of Cincinnati Method of treating diabetes using non-glycosylated apolipoprotein A-IV
JP6033433B2 (ja) 2012-07-25 2016-11-30 ユニバーシティ・オブ・シンシナティ アポリポタンパク質ａｉｖを用いて高血糖障害を治療する方法
AU2013295721B2 (en) 2012-07-25 2017-07-20 University Of Cincinnati Method of treating type I diabetes using apolipoprotein AIV
JP6629725B2 (ja) * 2014-06-23 2020-01-15 東亞合成株式会社 新規合成ペプチドおよびその利用
CN112546201A (zh) * 2019-09-26 2021-03-26 中国科学院生物物理研究所 人工脂蛋白颗粒apoA-Ⅳ脂肪体在治疗和/或预防糖尿病中的应用
CN113018459A (zh) * 2021-03-09 2021-06-25 百码科技(深圳)有限公司 一种基因治疗减肥的生物药剂及其制备方法
CN112891561A (zh) * 2021-03-09 2021-06-04 百码科技(深圳)有限公司 一种基因治疗脂肪肝的生物药剂及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
FR2686605B1 (fr) * 1992-01-27 1994-03-11 Rhone Poulenc Rorer Sa Nouveaux polypeptides, leur preparation et leur utilisation.
WO1994027629A1 (en) 1993-05-28 1994-12-08 Merck & Co., Inc. Method to control appetite and treat obesity
US6729075B2 (en) * 2000-10-19 2004-05-04 Wenger Corporation Audience seating system
NZ537006A (en) 2002-05-17 2008-01-31 Esperion Therapeutics Inc The use of apolipoprotein A-I Milano, for the manufacture ofa composition for treating preventing or reducing ischemic reperfusion injury in a tissue or organ
EP2051725A4 (en) * 2006-07-11 2011-06-15 Harkness Pharmaceuticals Inc METHOD FOR THE TREATMENT OF GRAIN WITH SATURATION FACTORS
US20100267052A1 (en) 2006-09-01 2010-10-21 American Type Culture Collection Compositions and methods for diagnosis and treatment of type 2 diabetes
WO2009116861A2 (en) * 2008-03-21 2009-09-24 Podiceps B.V. Diagnostic of pre-symptomatic metabolic syndrome
CN103833712B (zh) 2008-11-28 2016-02-03 中国医学科学院药物研究所 硝克柳胺化合物晶ii型、其制法和其药物组合物与用途
WO2012028522A1 (en) * 2010-08-30 2012-03-08 F. Hoffmann-La Roche Ag Alkaline feed
AU2012207301B2 (en) 2011-01-19 2016-05-19 University Of Cincinnati Apolipoprotein AIV as an antidiabetic peptide
AU2012366182B2 (en) 2012-01-19 2017-08-17 University Of Cincinnati Method of treating diabetes using non-glycosylated apolipoprotein A-IV
AU2013295721B2 (en) 2012-07-25 2017-07-20 University Of Cincinnati Method of treating type I diabetes using apolipoprotein AIV
JP6033433B2 (ja) 2012-07-25 2016-11-30 ユニバーシティ・オブ・シンシナティ アポリポタンパク質ａｉｖを用いて高血糖障害を治療する方法

Also Published As

Publication number Publication date
IL233351A0 (en) 2014-08-31
AU2012366182A1 (en) 2014-08-07
CN104066436B (zh) 2016-12-14
AU2012366182B2 (en) 2017-08-17
EP2804618B1 (en) 2018-03-07
JP2015506942A (ja) 2015-03-05
JP6310398B2 (ja) 2018-04-11
KR20140117565A (ko) 2014-10-07
MX357071B (es) 2018-06-22
AU2012366182A8 (en) 2015-06-18
EA028230B1 (ru) 2017-10-31
EP2804618A1 (en) 2014-11-26
MX2014008829A (es) 2014-10-24
CA2860782A1 (en) 2013-07-25
BR112014017141A2 (pt) 2019-09-24
US9951120B2 (en) 2018-04-24
EA201491369A1 (ru) 2015-03-31
US20150011469A1 (en) 2015-01-08
WO2013109342A1 (en) 2013-07-25
WO2013109342A8 (en) 2014-09-04
HK1203823A1 (en) 2015-11-06
CN104066436A (zh) 2014-09-24

Similar Documents

Publication Publication Date Title
IL253225B (en) Sulfamoyl-arylamides and their use as drugs to treat jaundice b
ZA201403795B (en) Formulations for the treatment of diabetes
IL237275A0 (en) Compounds for the treatment of paramoxovirus viral infections
IL233351A (en) Use of apolipoprotein a – iv without glycosylation for the preparation of diabetes medications
ZA201501977B (en) Orally administered medical composition
IL222890A0 (en) Medicaments for the treatment of il-1beta related conditions
SG11201401907TA (en) Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof
ZA201500229B (en) Combinations of modalities for the treatment of diabetes
AP2015008366A0 (en) 2-Phenyl-5-heterocyclyl-tetrahydro-2H-pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders
AP2013007179A0 (en) Glycoside derivatives and their uses for the treatment of diabetes
EP2867239A4 (en) OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES
IL232384A (en) Use of lupanate compounds or lupanic acid for the preparation of anti-gout drugs
IL234796B (en) Compounds for the treatment of diseases related to ischemia-reperfusion
ZA201400488B (en) Compounds for the treatment of cancers associated with human papillomavirus
HUP1200552A2 (en) Pharmaceutical compositions for the treatment of high blood pressure
IL232294B (en) Preparations for the treatment of diabetes
GB201207476D0 (en) pharmaceutical for the treatment of leishmaniasis
HUP1100245A2 (en) Pharmaceutical composition for the treatment of wounds
HK1193342A (en) Pharmaceutical combination for use in the treatment of diabetes type 2
AP2015008270A0 (en) Preparation for the treatment of tuberculosis
PL2812351T3 (pl) Kompozycja farmaceutyczna do leczenia stwardnienia rozsianego

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed